02 January 2022>: Clinical Research
Retrospective Study of 573 Patients with Heart Failure Evaluated for Coronary Artery Disease at Toulouse University Center, France
Antoine Deney 1ABCDEF* , Vanessa Nader 12ABCDEF* , Anthony Matta 13ABCDE , Romain Itier 1CDE , Pauline Fournier 1ABCD , Olivier Lairez 1ADF , Nathalie Pizzinat 4ACD , Didier Carrié 1ACD , Frédéric Boal 4ACD , Michel Galinier 1ACD , Oksana Kunduzova 4ACD , Rania Azar 2ACD , Jerome Roncalli 14ABCDEFG*DOI: 10.12659/MSM.934804
Med Sci Monit 2022; 28:e934804
Table 1 Characteristics of the studied population stratified by type of heart failure.
Studied populationN=573 | HFpEFN=89 | HFrEFN=484 | P-value | |
---|---|---|---|---|
Age | 68.28±12.25 | 72.53±9.72 | 67.50±12.51 | |
Male sex | 438 (76.44%) | 63 (70.78%) | 375 (77.48%) | 0.171 |
BMI | 27.89±18.104 | 27.65±6.565 | 27.93±19.501 | 0.893 |
Coronary artery disease | 320 (55.84%) | 50 (56.18%) | 270 (55.78%) | 0.945 |
Atrial fibrillation | 174 (30.37%) | 25 (28.09%) | 149 (30.78%) | 0.611 |
Chronic kidney disease | 266 (46.42%) | 45 (50.56%) | 221 (45.66%) | 0.500 |
Dyslipidemia | 164 (28.62%) | 39 (43.82%) | 125 (25.83%) | 0.001 |
Diabetes mellitus | 171 (29.84%) | 29 (32.58%) | 142 (29.34%) | 0.711 |
Hypertension | 309 (53.93%) | 61 (68.54%) | 248 (51.24%) | 0.006 |
Smoking | 144 (25.13%) | 11 (12.36%) | 133 (27.48%) | 0.001 |
Family history | 89 (15.53%) | 11 (12.36%) | 78 (16.12%) | 0.289 |
Valvulopathy | 224 (39.09%) | 29 (32.58%) | 195 (40.29%) | 0.181 |
Right ventricular dysfunction | 110 (19.20%) | 6 (6.74%) | 104 (21.49%) | 0.535 |
TAPSE | 16.77±4.45 | 16.45±3.488 | 16.78±4.50 | 0.811 |
PAPSE | 41.38±13.30 | 40.62±10.26 | 41.46±3.63 | 0.829 |
Pacemaker | 41 (7.16%) | 6 (6.74%) | 35 (7.23%) | 0.858 |
Defibrillator | 38 (6.63%) | 1 (1.12%) | 37 (7.64%) | 0.023 |
NYHA class | ||||
1 | 23 (4.01%) | 0 | 4 (0.82%) | 0.433 |
2 | 143 (24.96%) | 17 (19.10%) | 126 (26.03%) | |
3 | 149 (26.00%) | 20 (22.47%) | 129 (26.65%) | |
4 | 47 (8.20%) | 4 (4.49%) | 43 (8.88%) | |
Systolic blood pressure | 128.86±22.80 | 137.72±22.43 | 127.37±22.55 | 0.001 |
Diastolic blood pressure | 75.27±15.84 | 72.92±20.56 | 75.67±14.90 | 0.197 |
Heart rate | 82.07±20.79 | 77.91±17.95 | 82.76±21.16 | 0.081 |
Troponin | 143.87±543.08 | 112.13±212.21 | 149.21±580.79 | 0.726 |
NT-ProBNP | 5535.15±8523.84 | 4073.81±7245.54 | 5770.14±8697.02 | 0.140 |
β-blockers | 324 (56.54%) | 41 (46.06%) | 283 (58.47%) | 0.030 |
Diuretics | 328 (57.24%) | 50 (56.18%) | 278 (57.44%) | 0.809 |
Mineralocorticoids | 95 (16.58%) | 11 (12.36%) | 84 (17.35%) | 0.277 |
ACE/ARA | 289 (50.44%) | 51 (57.30%) | 238 (49.17%) | 0.164 |
ARNI | 45 (7.85%) | 3 (3.37%) | 42 (8.68%) | 0.087 |
Ivabradine | 7 (1.22%) | 0 | 7 (1.45%) | 0.603 |
SAPT | 172 (30.02%) | 36 (40.45%) | 136 (28.10%) | 0.041 |
DAPT | 47 (8.20%) | 8 (9.00%) | 39 (8.05%) | 0.893 |
DOAC+AVK | 165 (28.79%) | 27 (30.33%) | 138 (28.51%) | 0.799 |
AAP+OAC | 35 (6.11%) | 6 (6.74%) | 29 (6.00%) | 0.893 |
β-blockers | 480 (83.77%) | 58 (65.17%) | 422 (87.19%) | |
Diuretics | 439 (76.61%) | 62 (69.66%) | 377 (77.89%) | 0.067 |
Mineralocorticoids | 231 (40.31%) | 19 (21.35%) | 212 (43.80%) | |
ACE/ARA | 332 (57.94%) | 65 (73.03%) | 267 (55.16%) | 0.002 |
ARNI | 137 (23.90%) | 4 (4.49%) | 133 (27.48%) | |
Ivabradine | 19 (3.32%) | 2 (2.25%) | 17 (3.51%) | 0.752 |
SAPT | 120 (20.94%) | 33 (37.08%) | 87 (17.97%) | |
DAPT | 215 (37.52%) | 29 (32.58%) | 186 (38.43%) | 0.256 |
DOAC+AVK | 217 (37.87%) | 31 (34.83%) | 186 (38.43%) | 0.480 |
AP+OAC | 82 (14.31%) | 11 (12.36%) | 71 (14.67%) | 0.569 |
BMI – body mass index; APT – single anti-platelet therapy; DAPT – dual anti-platelet therapy; DOAC – direct oral anti-coagulant; AP+OAC – anti-platelet +oral anti-coagulant. |